164 related articles for article (PubMed ID: 31283775)
41. Assessing the impact of CMF-like/Anthracycline-based/Anthracycline-Taxane-based/dose-dense chemotherapy in dependency of positive axillary lymph nodes/hormone receptor-status/grading/T-stage on survival - A retrospective multi-centre cohort study of 3677 patients receiving adjuvant chemotherapy.
Schwentner L; Wöckel A; König J; Janni W; Blettner M; Kreienberg R; Van Ewijk R;
Eur J Cancer; 2014 Nov; 50(17):2905-15. PubMed ID: 25239681
[TBL] [Abstract][Full Text] [Related]
42. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes.
Fisher B; Dignam J; Tan-Chiu E; Anderson S; Fisher ER; Wittliff JL; Wolmark N
J Natl Cancer Inst; 2001 Jan; 93(2):112-20. PubMed ID: 11208880
[TBL] [Abstract][Full Text] [Related]
43. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy.
Gasparini G; Barbareschi M; Boracchi P; Verderio P; Caffo O; Meli S; Dalla Palma P; Marubini E; Bevilacqua P
Cancer J Sci Am; 1995; 1(2):131-41. PubMed ID: 9166466
[TBL] [Abstract][Full Text] [Related]
44. Positive nonsentinel lymph nodes are associated with poor survival in breast cancer: results from a retrospective study.
Si P; Zhang P; Chen T; Liu G; Lu H; Chen H; Wang C; Zhai B; Li W
Clin Transl Oncol; 2019 Aug; 21(8):1085-1092. PubMed ID: 30632009
[TBL] [Abstract][Full Text] [Related]
45. The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes.
Truong PT; Berthelet E; Lee J; Kader HA; Olivotto IA
Cancer; 2005 May; 103(10):2006-14. PubMed ID: 15812825
[TBL] [Abstract][Full Text] [Related]
46. [Optimal treatment of the axilla after positive sentinel lymph node biopsy in early invasive breast cancer. Early results of the OTOASOR trial].
Sávolt A; Musonda P; Mátrai Z; Polgár C; Rényi-Vámos F; Rubovszky G; Kovács E; Sinkovics I; Udvarhelyi N; Török K; Kásler M; Péley G
Orv Hetil; 2013 Dec; 154(49):1934-42. PubMed ID: 24292111
[TBL] [Abstract][Full Text] [Related]
47. Association between extent of axillary lymph node dissection and survival in patients with stage I breast cancer.
Sosa JA; Diener-West M; Gusev Y; Choti MA; Lange JR; Dooley WC; Zeiger MA
Ann Surg Oncol; 1998 Mar; 5(2):140-9. PubMed ID: 9527267
[TBL] [Abstract][Full Text] [Related]
48. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18.
Fisher ER; Wang J; Bryant J; Fisher B; Mamounas E; Wolmark N
Cancer; 2002 Aug; 95(4):681-95. PubMed ID: 12209710
[TBL] [Abstract][Full Text] [Related]
49. Response rate to neoadjuvant chemotherapy measured on imaging predicts early recurrence and death in breast cancer patients with lymph node involvements.
Nagashima T; Sakakibara M; Kadowaki M; Suzuki TH; Yokomizo J; Ohki Y; Miyoshi T; Kazama T; Nakatani Y; Miyazaki M
Acta Radiol; 2011 Apr; 52(3):241-6. PubMed ID: 21498357
[TBL] [Abstract][Full Text] [Related]
50. Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer.
Span PN; Tjan-Heijnen VC; Manders P; Beex LV; Sweep CG
Oncogene; 2003 Jul; 22(31):4898-904. PubMed ID: 12894232
[TBL] [Abstract][Full Text] [Related]
51. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
[TBL] [Abstract][Full Text] [Related]
52. Stage-to-stage comparison of neoadjuvant chemotherapy versus adjuvant chemotherapy in pathological lymph node positive breast cancer patients.
Lee NK; Shin KH; Park IH; Lee KS; Ro J; Jung SY; Lee S; Kim SW; Kim TH; Kim JY; Kang HS; Cho KH
Jpn J Clin Oncol; 2012 Nov; 42(11):995-1001. PubMed ID: 22911001
[TBL] [Abstract][Full Text] [Related]
53. PET/CT with
Teixeira SC; Koolen BB; Elkhuizen PH; Vrancken Peeters MT; Stokkel MP; Rodenhuis S; van der Noort V; Rutgers EJ; Valdés Olmos RA
Eur J Surg Oncol; 2017 Apr; 43(4):625-635. PubMed ID: 27847287
[TBL] [Abstract][Full Text] [Related]
54. Risk factors for regional nodal relapse in breast cancer patients with one to three positive axillary nodes.
Yates L; Kirby A; Crichton S; Gillett C; Cane P; Fentiman I; Sawyer E
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):2093-103. PubMed ID: 21530101
[TBL] [Abstract][Full Text] [Related]
55. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
56. Long-term follow-up of axillary node-positive breast cancer patients receiving adjuvant systemic therapy alone: patterns of recurrence.
Fisher BJ; Perera FE; Cooke AL; Opeitum A; Venkatesan V; Dar AR; Stitt L
Int J Radiat Oncol Biol Phys; 1997 Jun; 38(3):541-50. PubMed ID: 9231678
[TBL] [Abstract][Full Text] [Related]
57. Survival benefit of post-mastectomy radiotherapy in breast carcinoma patients with T1-2 tumor and 1-3 axillary lymph node(s) metastasis.
Duraker N; Demir D; Bati B; Yilmaz BD; Bati Y; Çaynak ZC; Sobutay E
Jpn J Clin Oncol; 2012 Jul; 42(7):601-8. PubMed ID: 22511807
[TBL] [Abstract][Full Text] [Related]
58. Therapeutic role of axillary lymph node dissection in patients with stage IV breast cancer: a population-based analysis.
Wu SG; Li FY; Chen Y; Sun JY; Lin HX; Lin Q; He ZY
J Cancer Res Clin Oncol; 2017 Mar; 143(3):467-474. PubMed ID: 27812853
[TBL] [Abstract][Full Text] [Related]
59. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
[TBL] [Abstract][Full Text] [Related]
60. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
